Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. boosted its position in Theravance Biopharma, Inc. (NASDAQ: TBPH) by 1,629.4% during the undefined quarter, according to its most recent Form 13F filing with the SEC. T
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
01:01pm, Monday, 08'th Dec 2025
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
10:55am, Friday, 05'th Dec 2025
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
10:46am, Friday, 05'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:3
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?
10:45am, Wednesday, 19'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma to Participate in Upcoming Investor Conferences
06:00am, Wednesday, 19'th Nov 2025
DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Eve
Here's Why Shares in Theravance Biopharma Exploded Today
02:14pm, Tuesday, 11'th Nov 2025
Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
11:10am, Tuesday, 11'th Nov 2025
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript
04:04am, Tuesday, 11'th Nov 2025
Theravance Biopharma, Inc. ( TBPH ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Co
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
07:57pm, Monday, 10'th Nov 2025
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to a loss of $0.06 per share a year ag
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Monday, 10'th Nov 2025
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRES
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
03:06pm, Thursday, 30'th Oct 2025
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
06:00am, Wednesday, 29'th Oct 2025
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS
